maybe that's why the shift towards UTI antibiotics in the recent months. seems that last presentation really had that flavour to it, as tho management were angleing at it. seems like R327 is a prime candidate for that particular application seeing the compound is excreted from the body via the kidneys and urinary tract. maybe they feel like that's the quickest way to get R327 to market/ a deal on the table. why else would you present a presentation with a specialist from switzerland talking about a deal done in that space.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)